AMGN - Amgen Inc Stock Price, Fair Value and News

335.06USD+0.76 (+0.23%)Market Closed

Market Summary

USD335.06+0.76

Market Closed

0.23%

AMGN Stock Price

View Fullscreen

AMGN RSI Chart

AMGN Valuation

Market Cap

179.7B

Price/Earnings (Trailing)

47.76

Price/Sales (Trailing)

6.09

EV/EBITDA

19.06

Price/Free Cashflow

25.32

AMGN Price/Sales (Trailing)

AMGN Profitability

EBT Margin

14.71%

Return on Equity

74.93%

Return on Assets

4.05%

Free Cashflow Yield

3.95%

AMGN Fundamentals

AMGN Revenue

Revenue (TTM)

29.5B

Rev. Growth (Yr)

21.98%

Rev. Growth (Qtr)

-9.14%

AMGN Earnings

Earnings (TTM)

3.8B

Earnings Growth (Yr)

-103.98%

Earnings Growth (Qtr)

-114.73%

Breaking Down AMGN Revenue

Last 7 days

Last 30 days

4.7%

Last 90 days

23.8%

Trailing 12 Months

42.1%

How does AMGN drawdown profile look like?

AMGN Financial Health

Current Ratio

1.42

Debt/Equity

11.96

Debt/Cashflow

0.13

AMGN Investor Care

Dividend Yield

2.57%

Dividend/Share (TTM)

8.64

Shares Dilution (1Y)

0.39%

Diluted EPS (TTM)

7.01

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	29.5B	0	0	0
2023	26.2B	26.6B	26.8B	28.2B
2022	26.3B	26.4B	26.3B	26.3B
2021	25.2B	25.5B	25.8B	26.0B
2020	24.0B	24.3B	25.0B	25.4B
2019	23.8B	23.6B	23.4B	23.4B
2018	22.9B	23.2B	23.3B	23.7B
2017	22.9B	23.1B	23.0B	22.8B
2016	22.2B	22.5B	22.6B	23.0B
2015	20.6B	20.8B	21.5B	21.7B
2014	19.0B	19.5B	19.7B	20.1B
2013	17.5B	17.7B	18.1B	18.7B
2012	15.9B	16.4B	16.8B	17.3B
2011	15.2B	15.3B	15.4B	15.6B
2010	14.9B	15.0B	15.0B	15.1B
2009	14.7B	14.6B	14.6B	14.6B
2008	0	14.8B	14.9B	15.0B
2007	0	0	0	14.8B

Get all data in R, Python etc through our Historical Stock Data APIs

About Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with BehÃƒÆ’Ã‚Â§et's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

CEO	Mr. Robert A. Bradway
WEBSITE	amgen.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	25200

Amgen Inc Frequently Asked Questions

What is the ticker symbol for Amgen Inc? What does AMGN stand for in stocks?

AMGN is the stock ticker symbol of Amgen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Amgen Inc (AMGN)?

As of Thu Jul 25 2024, market cap of Amgen Inc is 179.32 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AMGN stock?

You can check AMGN's fair value in chart for subscribers.

Is Amgen Inc a good stock to buy?

The fair value guage provides a quick view whether AMGN is over valued or under valued. Whether Amgen Inc is cheap or expensive depends on the assumptions which impact Amgen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AMGN.

What is Amgen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, AMGN's PE ratio (Price to Earnings) is 47.65 and Price to Sales (PS) ratio is 6.07. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AMGN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Amgen Inc's stock?

In the past 10 years, Amgen Inc has provided 0.133 (multiply by 100 for percentage) rate of return.